Dosing and Administration

XHANCE is easy to use¹

Please see Instructions for Use for detailed administration instructions.

How to Administer XHANCE
Dosing Information for XHANCE

To prime XHANCE for first use:

Full Prescribing Information

Remove the cap and shake the device well
Spray the device 7 times or until a fine mist is expelled

To use XHANCE²:

Full Prescribing Information

1 Seal

First, shake well. Then, using 1 or 2 hands, place your fingers on the indented grip BELOW the mouthpiece.

Gently insert the nosepiece into your nose to form a tight seal, then rotate to insert the flexible mouthpiece into your mouth while keeping the nosepiece deep in the nostril.

Keep a tight seal between the nosepiece and your nostril.

Full Prescribing Information

2 Aim

Aim the device upwards between your eyes.

It may help to use a mirror.

Full Prescribing Information

3 Blow

Take a deep breath and exhale hard into the mouthpiece, as if blowing up a balloon.

Blow, don’t sniff. Don’t block your other nostril.

Full Prescribing Information

4 Press

Keep blowing as you press the bottle with your thumb, releasing the medicine deep into your nasal passages.

Continue blowing hard while pressing the bottle. Repeat these steps for the other nostril.

XHANCE is administered in each nostril twice daily

Image of prescription pad showing how to write XHANCE for 1 spray per nostril twice daily with 5 refills The recommended dosage is
1 spray per nostril (equal to 186 mcg) twice daily.

1 XHANCE unit = 30 days

Image of prescription pad showing how to write XHANCE for 2 sprays per nostril twice daily with 5 refills XHANCE is also approved for
2 sprays per nostril (equal to 372 mcg) twice daily.

2 XHANCE units = 30 days

The maximum total daily dosage should not exceed 2 sprays in each nostril twice daily (8 sprays total). For best results, patients should use XHANCE regularly, twice daily.

Full Prescribing Information

Download the Dosing Card

Keep a reminder of the approved dosages of XHANCE.

View endoscopy videos taken before and after treatment with XHANCE.

See what makes XHANCE different.

Watch MOD Video

+

References:

Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.
Data on file. OptiNose US, Inc.

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor
patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing
has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after
administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial,
viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue
XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal
mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

References:

Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.
Data on file. OptiNose US, Inc.